Education
About Us
Working with TipRanks
Follow Us
Zentek (ZTEK)
NASDAQ:ZTEK
ZTEK Stock Chart & Stats
$0.69
-$0.05(-4.63%)
At close: 4:00 PM EST
$0.69
-$0.05(-4.63%)
Day’s Range― - ―
52-Week Range$0.54 - $1.84
Previous CloseN/A
Volume66.53K
Average Volume (3M)63.87K
Market Cap
$68.46M
Enterprise Value$92.60M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$1.92M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding107,543,560
10 Day Avg. Volume35,879
30 Day Avg. Volume63,873
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)11.24
Price to Sales (P/S)190.02
P/FCF Ratio-26.38
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue98.22
Enterprise Value/Gross Profit-131.33
Enterprise Value/Ebitda-11.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
IP & Advanced Materials FocusZentek's clear strategic focus on graphene and nanotech, plus stated R&D and IP development, provides durable product differentiation. Ownership of IP and multiple commercialization routes (manufacturing, licensing, partnerships) create optionality and long-term entry barriers across industrial and medical coatings markets.
Low Financial LeverageA very low debt-to-equity ratio gives Zentek structural financial flexibility: it reduces default risk, lowers interest burdens, and preserves capacity to raise capital or pursue partnerships. Over 2-6 months this improves runway and strategic optionality to advance commercialization without heavy interest drag.
High Revenue Growth RateA reported ~1,358% revenue growth rate indicates emerging commercial traction from a small base. Persisting high growth suggests product-market validation and scaling potential; sustainably growing top line helps justify continued R&D and partner investment if the company can preserve margins while expanding volumes.
Bears Say
Very Small Revenue BaseSub-$1M TTM revenue leaves the business far from commercial scale, limiting economies of scale and making fixed costs a larger share of revenue. This structural weakness increases sensitivity to single customers or product delays and constrains the firm's ability to self-fund growth over the next several months.
Negative Profitability And Cash BurnConsistent negative operating and free cash flow implies continued reliance on external financing or dilutive capital raises to fund operations. Structurally, this limits strategic freedom, risks shareholder dilution, and creates runway pressure until meaningful positive cash generation is achieved.
Gross Margin DeteriorationA move to negative gross margins signals structural cost or pricing problems at the product level. Even with rising revenue, negative unit economics hinder the path to profitability and make scaling riskier, reducing appeal to manufacturing partners and increasing the capital required to reach break-even.
Zentek News
ZTEK FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was $0.54 and its highest was $1.84 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is $68.46M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Jul 01, 2026 which is in 118 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Feb 17, 2026. The company reported -$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.017.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 107,543,560 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.674%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in ZTEK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 3.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth C$62.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.65%
12-Months-Change
Fundamentals
Return on Equity
-52.95%
Trailing 12-Months
Asset Growth
-22.95%
Trailing 12-Months
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
Quipt Home Medical
―
Sona Nanotech Inc
―
Ownership Overview
4.02% Insiders
0.05% Mutual Funds
0.95% Other Institutional Investors
94.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---